Yarrow Bioscience Inc（YARW）資訊與事件YARWYarrow Bioscience Inc

Jefferies and Others Jointly Manage Offering Priced Below $28.44

Jefferies, TD Cowen and Guggenheim are acting as joint book running managers for the offering. Offering was priced below last closing price of $28.44.

Yarrow Bioscience Commences Underwritten Public Offering

Yarrow Bioscience announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Yarrow. Yarrow intends to use the net proceeds from this offering to fund research and development expenses for Yarrow's pipeline and general corporate purposes, which may include working capital, capital expenditures and other general corporate purposes. Jefferies, TD Cowen and Guggenheim Securities are acting as joint book-running managers and LifeSci Capital is acting as lead manager for the proposed offering.

Yarrow Initiates Phase 2a/2b Trial for YB-101

"The second quarter was highly productive for Yarrow and included the initiation of our Phase 2a/2b clinical trial of YB-101, a potential first-in-class anti-TSHR antibody that represents a highly differentiated approach to treating both Graves' disease and thyroid eye disease. These two diseases converge on the TSHR, a single receptor that no approved therapy targets directly, giving Yarrow the unique opportunity to treat both conditions with a single molecule," said Rebecca V. Frey, PharmD, President and Chief Executive Officer of Yarrow. "With the merger with VYNE Therapeutics now complete and cash runway expected to fund operations into 2028, we're well-positioned to advance YB-101 in GD, where dosing is underway and Phase 2a data are expected in the second half of 2027. Additionally, GenSci continues its Phase 1 MAD study in TED in China, which we expect to inform our global TED development plans."